PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. BBIO (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that additional Phase 3 data on clinical outcomes from ATTRibute-CM, its study of acoramidis in ATTR-CM will be presented at the…Read More
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibuteCM Study in Patients with Transthyretin Amyloid Cardiomyopathy ATTRCM at the American Heart Association AHA Scientific Sessions 2023 BridgeBio Pharma NASDAQBBIO
